IOVA

7.38

2.22% 0.16

Handel nachbörslich: 7.48 0.10 +1.36%

Iovance Biotherapeutics Inc (IOVA)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt IOVA? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$7.22

Offen:

$7.17

24-Stunden-Volumen:

9.57M

Relative Volume:

1.64

Marktkapitalisierung:

$2.25B

Einnahmen:

$32.77M

Nettoeinkommen (Verlust:

$-440.22M

KGV:

-3.2946

EPS:

-2.24

Netto-Cashflow:

$-400.48M

1W Leistung:

-5.75%

1M Leistung:

-9.34%

6M Leistung:

-7.40%

1J Leistung:

+2.79%

1-Tages-Spanne:

$7.07

$7.44

1-Wochen-Bereich:

$7.0602

$8.14

52-Wochen-Spanne:

$6.70

$18.33

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Firmenname

Iovance Biotherapeutics Inc

Sektor

Healthcare (1176)

Branche

Biotechnology (673)

Telefon

(650) 260-7120

Adresse

825 INDUSTRIAL ROAD, SAN CARLOS

Mitarbeiter

557

Twitter

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

IOVA's Discussions on Twitter

Vergleichen Sie IOVA mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
IOVA Iovance Biotherapeutics Inc	7.38	2.25B	32.77M	-440.22M	-400.48M	-1.67
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-10-24	Eingeleitet	UBS	Buy
2024-07-29	Herabstufung	Piper Sandler	Overweight → Neutral
2023-11-20	Eingeleitet	Goldman	Buy
2023-09-18	Bestätigt	Barclays	Overweight
2023-05-30	Hochstufung	Wells Fargo	Equal Weight → Overweight
2023-03-27	Fortgesetzt	Wells Fargo	Equal Weight
2023-01-27	Hochstufung	Piper Sandler	Neutral → Overweight
2022-12-09	Herabstufung	Goldman	Buy → Neutral
2022-10-31	Eingeleitet	Guggenheim	Neutral
2022-08-18	Fortgesetzt	Wells Fargo	Equal Weight
2022-01-28	Hochstufung	Stifel	Hold → Buy
2021-12-07	Fortgesetzt	Cowen	Outperform
2021-06-10	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform
2021-05-20	Herabstufung	Piper Sandler	Overweight → Neutral
2021-05-19	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2021-05-19	Herabstufung	Stifel	Buy → Hold
2021-05-03	Eingeleitet	Truist	Buy
2021-04-16	Eingeleitet	Goldman	Buy
2021-03-08	Hochstufung	H.C. Wainwright	Neutral → Buy
2020-12-15	Herabstufung	H.C. Wainwright	Buy → Neutral
2020-10-06	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-04-22	Eingeleitet	Mizuho	Buy
2020-03-04	Eingeleitet	Barclays	Overweight
2020-02-26	Bestätigt	H.C. Wainwright	Buy
2020-02-26	Bestätigt	Oppenheimer	Outperform
2019-12-18	Eingeleitet	JMP Securities	Mkt Outperform
2019-10-01	Eingeleitet	Stifel	Buy
2019-04-29	Eingeleitet	Piper Jaffray	Overweight
2019-02-28	Bestätigt	Chardan Capital Markets	Buy
2019-02-07	Eingeleitet	Robert W. Baird	Outperform
2018-12-31	Fortgesetzt	B. Riley FBR	Buy
2018-07-06	Bestätigt	Chardan Capital Markets	Buy
2018-04-10	Hochstufung	B. Riley FBR, Inc.	Neutral → Buy
2018-03-13	Bestätigt	B. Riley FBR, Inc.	Neutral
2018-02-23	Herabstufung	B. Riley FBR, Inc.	Buy → Neutral
2018-01-25	Bestätigt	H.C. Wainwright	Buy
2017-11-01	Bestätigt	B. Riley FBR, Inc.	Buy

Alle ansehen

Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten

04:31 AM

Barclays PLC Raises Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

04:31 AM

01:06 AM

Where are the Opportunities in (IOVA) - Stock Traders Daily

01:06 AM

Dec 20, 2024

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

Dec 20, 2024

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire Inc.

Dec 20, 2024

Dec 19, 2024

Insiders' US$48.3m Investments In Red Following Iovance Biotherapeutics' US$402m Dip In Market Value - Simply Wall St

Dec 19, 2024

Dec 17, 2024

KEI Comments on NIH Exclusive License to Iovance for T-cell Vaccine for Cancer Treatment - Knowledge Ecology International

Dec 17, 2024

Dec 16, 2024

Iovance Biotherapeutics: Amtagvi Launch Growing, But Stock Isn't (NASDAQ:IOVA) - Seeking Alpha

Dec 16, 2024

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Sees Significant Increase in Short Interest - MarketBeat

Dec 16, 2024

Dec 15, 2024

State Street Corp Grows Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Dec 15, 2024

Dec 13, 2024

Iovance Biotherapeutics' SWOT analysis: promising TIL therapy stock faces growth hurdles - Investing.com India

Dec 13, 2024

Dec 12, 2024

Interesting IOVA Call Options For January 2025 - Nasdaq

Dec 12, 2024

Prediction: This Stock Will Beat the Market in 2025 - Yahoo Finance

Dec 12, 2024

Dec 11, 2024

BNP Paribas Financial Markets Trims Stock Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Dec 11, 2024

Dec 09, 2024

Iovance Biotherapeutics' SWOT analysis: stock shows promise amid challenges By Investing.com - Investing.com Nigeria

Dec 09, 2024

Iovance Biotherapeutics: Steady Progress (NASDAQ:IOVA) - Seeking Alpha

Dec 09, 2024

Dec 08, 2024

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Dec 08, 2024

Dec 07, 2024

Charles Schwab Investment Management Inc. Has $17.96 Million Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Dec 07, 2024

Dec 06, 2024

Iovance's (IOVA) Q4 Earnings & Sales Fall Short of Estimates - MSN

Dec 06, 2024

Dec 03, 2024

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a favorite amongst institutional investors who own 63% - Yahoo Finance

Dec 03, 2024

Nov 30, 2024

Braidwell LP Has $2.05 Million Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Nov 30, 2024

Nov 29, 2024

(IOVA) On The My Stocks Page - Stock Traders Daily

Nov 29, 2024

Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect - MSN

Nov 29, 2024

Intech Investment Management LLC Makes New $920,000 Investment in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Nov 29, 2024

Nov 28, 2024

IOVAIovance Biotherapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Nov 28, 2024

Nov 27, 2024

Is Iovance Biotherapeutics Stock a Millionaire Maker? - MSN

Nov 27, 2024

Nov 26, 2024

Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer - GlobeNewswire

Nov 26, 2024

Iovance Biotherapeutics (STU:2LB) Operating Cash Flow per S - GuruFocus.com

Nov 26, 2024

Iovance Biotherapeutics (NASDAQ:IOVA) delivers shareholders favorable 68% return over 1 year, surging 10.0% in the last week alone - Simply Wall St

Nov 26, 2024

IOVA (Iovance Biotherapeutics) Total Assets : $991.12 Mil (As of Sep. 2024) - GuruFocus.com

Nov 26, 2024

Victory Capital Management Inc. Buys 115,387 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Nov 26, 2024

Nov 25, 2024

IOVA (Iovance Biotherapeutics) Cash Flow from Financing : $389.32 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 25, 2024

Nov 24, 2024

Got $1,500? Buy Iovance Biotherapeutics Now and Don't Look Back - MSN

Nov 24, 2024

Landscape Capital Management L.L.C. Takes $615,000 Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Nov 24, 2024

Eagle Asset Management Inc. Lowers Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Nov 24, 2024

Nov 23, 2024